China is adding semaglutide (Ozempic) to its National Essential Drug List, effective September 1, making it the second GLP-1 drug to earn that status after liraglutide. The move means all public hospitals — even in remote rural areas — must prioritize stocking the drug. Experts say it also sets the stage for generics to gain broad access once approved, a significant shift in the world's largest diabetes market.
China is adding injectable semaglutide — the active ingredient in Novo Nordisk's Ozempic — to its National Essential Drug List (NEDL), effective September 1. The designation requires all public hospitals to prioritize stocking the drug, meaning it should now be available even in remote rural facilities. Semaglutide becomes the second GLP-1 medication on the list, following the older drug liraglutide.
The move carries major implications for access and competition. Semaglutide's patent expired in China in March 2026, and while Novo Nordisk retains regulatory data protection until early next year, experts say the NEDL listing will "pave the way for generics to be broadly listed" once they clear approval. China holds the world's highest number of adults with diabetes, making this a consequential policy shift for public health.
Key Takeaways:
Why it matters: With China home to more adults with diabetes than any other country, placing semaglutide on the essential medicines list could dramatically expand treatment access — and accelerate the entry of lower-cost generics into one of the world's biggest pharmaceutical markets.
